Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 9 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
CUREVAC SE has 14 pending office actions in Biotechnology & Pharmaceuticals. The profile identifies 14 distinct examiners and 10 distinct art units, indicating broad distribution across examination assignments, with more examiner assignments than art-unit assignments.
BURKHART, MICHAEL D is the identified busiest examiner, with 1 pending matter. No examiner accounts for a dominant share of the pending portfolio in the supplied data, so counsel should maintain separate matter-level tracking rather than relying on one examiner relationship.
The difference between examiner and art-unit dispersion suggests that some technical assignments are shared across examiners. Portfolio management should therefore coordinate claim strategy across related art-unit work while preserving examiner-specific response records.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (17%) |
| §103 only | 5 (42%) |
| Multi-statute (no §101) | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
| HAM, JIEUN | 1 | 45.5% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 11d overdue |
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | MIANO, JOSEPH PAUL | — |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | HOERNER, PAUL ELLSWORTH | — |
| 18558531 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | RAHMAN, MASUDUR | — |
| 18283601 | IMMUNOGENIC COMPOSITIONS | CHEN, STACY BROWN | — |
| 18320187 | ARTIFICIAL NUCLEIC ACID MOLECULES | GRAY, JESSICA | — |
| 18043317 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 11d overdue |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | RYAN, DOUGLAS CHARLES | 12d |
| 18320598 | RNA SEQUENCE ADAPTATION | SULLIVAN, STEPHANIE LAUREN | 62d |
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | MIANO, JOSEPH PAUL | — |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | HOERNER, PAUL ELLSWORTH | — |
| 18558531 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | RAHMAN, MASUDUR | — |
| 18283601 | IMMUNOGENIC COMPOSITIONS | CHEN, STACY BROWN | — |
| 18043317 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1672 | 2 |
| 1637 | 2 |
| 1631 | 1 |
| 1611 | 1 |
| 1632 | 1 |
| 1633 | 1 |
| 1682 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | MIANO, JOSEPH PAUL | 1631 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | HOERNER, PAUL ELLSWORTH | 1611 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 1632 | §103§112 | Non-Final OA | 11d overdue | Pending | Jan 17, 2024 |
| 18558531 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | RAHMAN, MASUDUR | 1633 | §101§102§103 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | RYAN, DOUGLAS CHARLES | 1635 | §103 | Final Rejection | 12d | Pending | Sep 29, 2023 |
| 18283601 | IMMUNOGENIC COMPOSITIONS | CHEN, STACY BROWN | 1672 | §101§102DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18320598 | RNA SEQUENCE ADAPTATION | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 62d | Pending | May 19, 2023 |
| 18320187 | ARTIFICIAL NUCLEIC ACID MOLECULES | GRAY, JESSICA | 1682 | §102§103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18043317 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | HAM, JIEUN | 1643 | §103 | Final Rejection | 93d overdue | Pending | Jan 30, 2023 |
| 17199120 | TARGETS FOR RNA THERAPEUTICS | MCKILLOP, JOHN CHARLES | 1637 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17045236 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 72d overdue | Pending | Oct 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCUREVAC SE has 12 pending office actions as of October 2026, spread across 9 art units and 12 examiners.
Joseph Paul Miano has the most, with 1 of CUREVAC SE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
